

## Confirmed Speakers

### Plenary Speakers

**Towards an Understanding of Cellular Drug Efficiency as a Way to Control Molecular Obesity (PL20)**

**Paul Ehrlich Prize Lecture  
Trip in Drug Discovery (PL01)**



Prof. Jean-Daniel BRION  
(UNIVERSITÉ PARIS-SUD, Chatenay-Malabry, France)

**The Discovery and Optimization of Benzimidzoles as Selective NAV1.8 Blockers for the Treatment of Pain (PL06)**



Dr Alan BROWN  
(STRATIFIED MEDICAL, Deal, United Kingdom)

**Conquering the p53-MDM2 Protein-Protein Interaction Target at Novartis (PL21)**



Dr Pascal FURET  
(NOVARTIS, Basel, Switzerland)

**Advances in Structure Based Drug Discovery of Membrane Protein Targets (PL14)**



Dr Michael HENNIG  
(LEADXPPO, Villigen, Switzerland)

**Discovery of the Type II Kinase Inhibitor LY3009120; a Pan-RAF Inhibitor Showing Minimal Paradoxical Activation and Anti-Cancer Activity Against BRAF or RAS Mutant Tumor Cells (PL22)**



Dr James R. HENRY  
(ELI LILLY & CO., Indianapolis, United States)

**Nanocyclix: a Chemical Biology Approach for Next Generation Kinase Inhibitors (PL08)**



Dr Jan HOFLACK  
(ONCODESIGN, Dijon, France)

**Molecular Imaging Agents Based on Lanthanide Complexes (PL17)**



Dr Eva JAKAB-TOTH  
(CNRS, Orléans, France)

**Optimization and Exploration of Bradykinin 1 Receptor Antagonists for Inflammation (PL07)**



Dr Sven KÜHNERT  
(GRUENENTHAL GMBH, Aachen, Germany)

## Confirmed Speakers

### Human Proteomes – from Basic Biology to Understanding Drug Action (PL02)



Prof. Bernhard KÜSTER  
(TECHNICAL UNIVERSITY MUNICH, Munich, Germany)

### Protein Total Synthesis and the Challenge of Understanding MET Tyrosine Kinase Receptor Activation (PL11)



Dr Oleg MELNYK  
(CNRS / UNIVERSITY OF LILLE / PASTEUR INSTITUTE OF LILLE, Lille, France)

### The Realisation of Activity-Directed Synthesis (PL19)



Prof. Adam NELSON  
(UNIVERSITY OF LEEDS, Leeds, United Kingdom)

### Discovery of Selective Dopaminergic D3 Receptor Antagonists with Potent 5HT6 Affinity (PL10)



Dr Jean-Claude ORTUNO  
(INSTITUT DE RECHERCHES SERVIER, SURESNES, France)

### Innovative Approaches to Control Metabotropic Glutamate Receptor Activity in the Brain (PL15)



Dr Jean-Philippe PIN  
(CNRS-UNIVERSITY OF MONTPELLIER, Montpellier, France)

### MT5-MMP, a New Potential Therapeutic Target in Alzheimer's Disease (PL09)



Dr Santiago RIVERA  
(CNRS / AIX-MARSEILLE UNIVERSITY, Marseille, France)

### Development of Novel Antiangiogenic Agents for the Treatment of Retinal Neovascularization via Integration of Chemistry and Biology (PL12)



Prof. Young-Ger SUH  
(SEOUL NATIONAL UNIVERSITY, Pocheon-si, Korea, South)

### Protein Modification: from Chemical Biology to Drug Discovery (PL04)



Prof. Edward TATE  
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

### Novel Fluorogenic Probes for In Vivo Imaging of Tiny Tumors and Super-Resolution Imaging in Living Cells (PL18)

## Confirmed Speakers



Prof. Yasuteru URANO  
(THE UNIVERSITY OF TOKYO, Tokyo, Japan)

### The Design of mGluR Modulators for CNS Disorders (PL16)



Dr Michiel VAN GOOL  
(JANSSEN R&D, Toledo, Spain)

### Design of Chemical Probes Acting on Emerging Targets Assisted by Online Computational Tools (PL13)



Dr Bruno VILLOUTREIX  
(INSERM/UNIVERSITY PARIS DIDEROT, Paris, France)

### Pierre Fabre Award for Therapeutic Innovation A Scien-trepeneur Journey From Digital to In-vivo Organic Chemistry (PL23)



Dr Alain WAGNER  
(CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France)

### A Role of SIRT2 in Cellular Response to Environmental Signals (PL05)



Dr Minoru YOSHIDA  
(RIKEN ADVANCED SCIENCE INSTITUTE (ASI), Saitama, Japan)

### Target Deconvolution Efforts Around Wnt Pathway Screen Reveal Parallel Mechanisms of Action for 1,2,3-Thiadiazole-5-Carboxamide Series (PL03)



Dr Andrew ZHANG  
(ASTRAZENECA, Waltham, United States)

## Keynote Speakers

### Development of Potent Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) (KL03)



Dr Céline CANO  
(NEWCASTLE CANCER CENTRE, Newcastle upon Tyne, United Kingdom)

### Original Serotonergic Multi-Target Directed Ligands against Alzheimer's Disease (KL02)



Dr Sylvie CLAEYSEN  
(INSTITUT DE GÉNOMIQUE FONCTIONNELLE / CNRS / INSERM, Montpellier, France)

### Discovery of GLPG1690: a First-in-Class Autotaxin Inhibitor in Clinical Development for the Treatment of Idiopathic Pulmonary Fibrosis (KL01)

## Confirmed Speakers



Dr Nicolas DESROY  
(GALAPAGOS, Romainville, France)

### Fragment-Based Design of ITK Inhibitors (KL06)



Dr Steven DURRANT  
(VERTEX PHARMACEUTICALS (EUROPE) LTD, Abingdon, United Kingdom)

### E.coli Anti-Adhesives, Potential Therapeutics for Crohn's Disease? (KL08)



Dr Sébastien GOUIN  
(UNIVERSITY OF NANTES, Nantes, France)

### Structure Guided Drug Discovery: Merits and Pitfalls Through the Example of Two Kinase Projects (KL04)



Dr Andras KOTSCHY  
(SERVIER RESEARCH INSTITUTE OF MEDICINAL CHEMISTRY, Budapest, Hungary)

### NMR for Chemical Biology and Drug Discovery (KL05)



Dr Isabelle KRIMM  
(CNRS / UNIVERSITY OF LYON 1, Lyon, France)

### Inhibiting Chromatin Assembly by Targeting Histone Chaperones (KL07)



Dr Françoise OCHSENBEIN  
(CEA SACLAY, Gif-sur-Yvette, France)